# Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke

> **NCT00141011** · PHASE3 · TERMINATED · sponsor: **Neurobiological Technologies** · enrollment: 277 (actual)

## Conditions studied

- Stroke
- Cerebral Ischemia
- Brain Infarction

## Interventions

- **DRUG:** Ancrod (Viprinex)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00141011
- **Lead sponsor:** Neurobiological Technologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-09
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 277 (ACTUAL)
- **Why stopped:** Futility
- **Last updated:** 2009-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00141011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00141011, "Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT00141011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*